Journal of Pharmacology and Pharmacotherapeutics

MOLECULES OF THE MILLENNIUM
Year
: 2014  |  Volume : 5  |  Issue : 3  |  Page : 222--224

Delamanid: A new armor in combating drug-resistant tuberculosis


Alphienes Stanley Xavier, Mageshwaran Lakshmanan 
 Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India

Correspondence Address:
Alphienes Stanley Xavier
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605 006
India

Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.


How to cite this article:
Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug-resistant tuberculosis.J Pharmacol Pharmacother 2014;5:222-224


How to cite this URL:
Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother [serial online] 2014 [cited 2021 Jan 22 ];5:222-224
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2014;volume=5;issue=3;spage=222;epage=224;aulast=Xavier;type=0